Leveraging genetic ancestry continuum information to interpolate PRS for admixed populations

Yunfeng Ruan[1], Rohan Bhukar[1,2], Aniruddh Patel[1,2,3], Satoshi Koyama[1,2,3,4], Leland Hull[5,6], Buu Truong[1,2,3,8], Whitney Hornsby[1,2], Haoyu Zhang[7], Nilanjan Chatterjee[9,10], Pradeep Natarajan[1,2,3,6]

Affiliations:
1. Program in Medical and Population, Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA, USA
2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
3. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA, USA
4. Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
5. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA
6. Department of Medicine, Harvard Medical School, Boston, MA, USA
7. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
8. Department of Genetic Epidemiology and Statistical Genetics, Harvard T.H. School of Public Health, Cambridge, MA, US
9. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
10. Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Please address correspondence to:
Pradeep Natarajan, MD MMSc
185 Cambridge Street, CPZN 5.238
Boston, MA 02446
617-726-1843
pnatarajan@mgh.harvard.edu

Funding:
P.N. is supported by NHGRI U01HG011719 and NHLBI R01HL127564. N.C is supported by NHGRI U01HG011719 and R01HG010480. A.P.P. is supported by NHLBI K08HL168238.

Disclosures:
P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, Novo Nordisk, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. All other

51 authors report no conflicts.

Abstract

The relatively low representation of admixed populations in both discovery and fine-
tuning individual-level datasets limits polygenic risk score (PRS) development and
equitable clinical translation for admixed populations. Under the assumption that the
most informative PRS weight for a homogeneous sample varies linearly in an
ancestry continuum space, we introduce a Genetic **Dis**tance-assisted PRS
Combination Pipeline for **Div**erse Genetic **A**ncestrie**s** (**DiscoDivas**) to interpolate a
harmonized PRS for diverse, especially admixed, ancestries, leveraging multiple
PRS weights fine-tuned within single-ancestry samples and genetic distance.
DiscoDivas treats ancestry as a continuous variable and does not require shifting
between different models when calculating PRS for different ancestries. We
generated PRS with DiscoDivas and the current conventional method, i.e. fine-tuning
multiple GWAS PRS using the matched or similar ancestry samples. DiscoDivas
generated a harmonized PRS of the accuracy comparable to or higher than the
conventional approach, with the greatest advantage exhibited in admixed individuals.
67

Introduction/Main

Individuals who are not of European ancestry remain underrepresented in genome-
wide association studies (GWAS), which at least partly explains why polygenic risk
score (PRS) performance is generally reduced in this population when compared
with individuals of European ancestry[1]. Within the constraints of existing data, the
current principal solution to increase the PRS accuracy among non-European
individuals is to fine-tune a combination of PRS derived from multiple populations or
multiple traits with the individual-level data of a training cohort[2–6]. However, PRS
accuracy decays as the genetic distance between the fine-tuning and testing
samples increases[7]. Relative to the vast diversity across the genetic ancestry
continuum, the existing and near-term individual-level datasets that can be used for
fine-tuning PRS combinations remains very sparse. Most existing individual-level
genotype data are mainly collected from single-ancestry populations and therefore
admixed populations are left underrepresented or are largely excluded from analysis
[8–11]. Additionally, fine-tuning and testing samples that are labeled as "from the same
superpopulation" are often truly genetically heterogeneous [10,12–15], leading to variable
accuracy within such samples.
85
PRS analysis across diverse ancestries may also be limited by inconsistency. The
raw PRS distributions of the same model varies by ancestry and therefore the raw
PRS values for individuals of different genetic ancestries should not be directly
compared without ancestry correction[16–18]. Although prior research[16,18,19] has shown
that regressing out the top principal components of ancestry (PCA) from the PRS can
unify the PRS distributions of different ancestries (i.e., the mean and standard
deviation of corrected PRS sampled from different populations can become very
close), the inconsistency is only partially solved. In the application of PRS across
diverse ancestries, one would have to use one PRS model for all the individuals,
causing inconsistent PRS accuracy, or use several discrete PRS models for different
individuals approximating superpopulations also causing inconsistent PRS modelling
and accuracy.

Given these issues and the increasing clinical use of PRS[20–22], PRS generation for
diverse and admixed genetic ancestries with more consistent accuracy and more
unified PRS distributions is critically needed. We devised a method, DiscoDivas, a
Genetic **Dis**tance-assisted PRS **Co**mbination Pipeline for **Div**erse Genetic
Ancestrie**s**, to generate PRS across the genetic ancestry continuum. This method is
based on the recent observation[7] that the PRS accuracy in the testing data decays
approximately linearly as the genetic distance between the fine-tuning and samples
increases, and that the genetic distance can be approximated by Euclidian distance
of PCA based on the global ancestries[7]. Based on this observation, we assumed that
the most informative PRS weights for a sample can be linearly interpolated from the
currently available PRS weights that are fine-tuned in the ancestries surrounding it in
the global ancestry-based PCA space with the interpolation weights based on the
Euclidian distance of the PCA. In summary, DiscoDivas calculates PRS for diverse
and admixed genetic ancestries whose genetic data may not be sufficiently powerful
alone to train a PRS model by linearly interpolating the multiple PRS fine-tuned in
ancestries whose genetic data are more available. We evaluated its performance in
simulated and empiric data.
116

Results

Overview of DiscoDivas

DiscoDivas combines PRS fine-tuned in different fine-tuning samples - generally from
different single-ancestry populations - to linearly interpolate PRS for individuals of
diverse genetic ancestries, treating ancestry as a continuous variable. The rationale
for PRS combination is based on the observation that the correlation of the most
informative PRS weight for two samples of different ancestry drops as the genetic
distance, represented by Euclidean distance of global ancestry-based PCA,
increases[7]. Therefore, the best PRS weight for an ancestry representation can be
linearly interpolated from other PRS weights fine-tuned in other ancestries with the
additional consideration of the genetic distance between the samples (Figure 1).
128

Under the same principle of interpolating the PRS weight, the best PRS can be
interpolated from several PRS calculated using the weight fine-tuned in other
ancestries. Since generating individual-specific PRS weights in a testing dataset
causes redundant calculation and given the difficulty of normalizing information from
different datasets, we combine the PRS instead of the SNP weights. The PRS of
individuals in the testing sample is a linear combination of PRS based on the SNP
weights fine-tuned in different fine-tuning samples:

136
$$PRS_i = \sum w_{i,k} PRS_{i,k}$$

where $PRS_{i,k}$ is the PRS of testing individual i calculated using the weight fine-tuned
in the fine-tuning sample k; $w_{i,k}$ is the combination coefficient mainly based on the
reciprocal of the PCA Euclidean distance between the testing individual and median
point of the fine-tuning sample $D_{i,k}$. Note that the input PRS and PCA should be of
the same scale: all the individuals are projected to the same PCA space based on a
global ancestry reference panel and the PRS input $PRS_{i,k}$ is the raw PRS regressed
out the top PCs and then standardized. Additionally, we recommend including all
available discovery GWAS for PRS in each PRS model fine-tuned in the single-

ancestry sample to maximize the PRS accuracy, as indicated in Figure 1.
Nevertheless, DiscoDivas is a flexible framework that allows the different sets of
discovery GWAS and fine-tuning method used in different fine-tuning samples.
148
In addition to the PCA distances, other factors are included in the model. First, since
some fine-tuning samples are more correlated than others (e.g., EAS and SAS are
more correlated than AFR and EUR), the combination coefficients should be further
modified by these correlations, which can also be extracted from the PCA Euclidean
distances. Second, since PRS fine-tuned in each of the fine-tuning samples may be
of differing qualities (e.g., when the PRS model fine-tuned in different samples are
based on GWAS of different sample sizes or populations), the quality of the PRS
trained with each of the training data will vary and should be taken into account when
combining the PRS. Thus, the combination coefficient $w_{i,k}$ in the previous formula is
a function of multiple factors:

$$w_{i,k} = f\left(\frac{1}{D_{i,k}}, G, r_k\right)$$

159   where $\frac{1}{D_{i,k}}$ is the reciprocal of PCA Euclidean distance between the individual i and
160   the fine-tuning sample k; G is the matrix of PCA Euclidean distance between fine-
161   tuning samples; r_k is the parameter describing the quality of training fine-tuning
162   samples. A more detailed description of defining $w_{i,k}$ is given in the supplementary
163   method section entitled 'Methodological Details of DiscoDivas'.
164
The PRS input for DiscoDivas in this study was the multi-GWAS PRS fine-tuned in
AFR, EAS, EUR, and SAS fine-tuning samples with the conventional method pipeline
as mentioned above (see the following section titled "Overview of multi-population
GWAS PRS model" for more detailed information of the input PRS). The interpolation
of these four PRS is based on the PCA calculated using the 1000 Genomes
reference panel. For most of the PRS analysis conducted in in the present study, the
input PRS of DiscoDivas are based on the same set of discovery GWAS and the
fine-tuning datasets are sufficiently large to generate a stable result. Therefore, we
assumed that all the input PRS can be viewed as of equal quality and their parameter
for PRS quality r_k can be viewed as a constant value in the present study.

176
Figure 1: The workflow of comparing DiscoDivas with the existing method. Left: The ideal situation
for the existing method is to fine-tune a PRS model that contains multiple GWAS with matched fine-
tuning data, which is not currently available for many under-represented populations. Right: DiscoDivas
first fine-tunes the PRS in the available ancestries, which are currently AFR, EAS, EUR, and SAS, and
interpolates PRS for diverse ancestry groups based on these fine-tuned PRS. In this plot, POP refers to
any ancestry for which the PRS is to be calculated.

183
A common approach for constructing PRS is to include as much genome-wide
association study (GWAS) summary statistic data as possible in the discovery
data[5,23,24]. The GWAS data is typically then processed by PRS methods that will
adjust the SNP effect size using a set of hyper-parameters. Individual-level data of an
independent fine-tuning sample is used to fine-tune the hyper-parameters across
PRS methods and the combination of the fine-tuned PRS. The resulting PRS is
expected to perform the best in samples of matched ancestry with the fine-tuning
sample.
192

The current approach, as shown in the left panel of Figure 1, is to use the multi-
GWAS PRS fine-tuned in the matched sample or the closest approximation when the
matched sample is unavailable. The pipeline of adjusting SNP effect sizes and
combining information from different GWAS varies widely. Without loss of generality,
we built the following pipeline as a representation of the current conventional method:
we first adjusted the SNP effect size of each of the summary statistical GWAS
datasets by a Bayesian method and then chose the most predictive PRS from all the
PRS generated under different hyper-parameters. For simulated GWAS data, we
used PRS-CS[25] to adjust the SNP effect size and LDpred2[26] for real GWAS. Then
we used the fine-tuning data to first select the most predictive PRS based on each
GWAS and then to train the linear combination of the most predictive single-GWAS
PRS with a linear regression model. The final PRS model generated from each of the
fine-tuning datasets is a linear combination of PRS. For the empiric data set, the PRS
were fine-tuned controlling for the following covariates: top 20 PCA, sex, and age.
We used AFR, EAS, EUR, SAS, AMR, and admixed samples to fine-tune the PRS. A
more detailed description of generating PRS weight from the one fine-tuning data
was given in Supplementary method section entitled 'Methodological Details of PRS
Construction Using a Single Fine-tuning Dataset'.
211

Simulated data results

Summary-level GWAS used as discovery data were generated based on simulated
genotype of AFR, EAS, EUR, and SAS population based on 1000 Genomes[27]
reference as described in the previous publication provided by Zhang et al[6]. Fine-
tuning and testing samples were simulated based on UKBB genotype data. From
each ancestry group of AFR, EAS, EUR, SAS, and other (OTH) for admixed
individuals whose PCA information was not matched with any of the five ancestries
by 1000 Genome reference definition, 1.3k individuals were used as the training fine-
tuning datasets (See supplementary method section entitled 'Generating data for
simulation analysis'). The phenotype of discovery, fine-tuning, and testing data were
generated using the same pipeline and parameters: the phenotypes of 100, 300,
1,000, or 10,000 causal SNPs and heritability = 0.6 were simulated. Scenarios of
shared causal SNP with effect size constant across different ancestries and shared
causal SNP with effect size varying across population are both simulated. We used
up to 100,000 simulated individuals from AFR, EAS, EUR, and SAS to generate the
discovery summary statistic GWAS dataset with PLINK2[28] and left the remaining
samples out for other downstream analyses.
229
230   We primarily focused on the PRS performance in the admixed testing cohort.
231   DiscoDivas, which is based on PRS fine-tuned in AFR, EAS, EUR, and SAS, was
232   compared with the conventional PRS fine-tuned in the matched admixed fine-tuning
233   sample in scenarios of different causal SNP numbers, different discovery GWAS
234   sample sizes, and different causal SNP distribution across ancestry (See Figure 2)
235

236
Figure 2 Relative R^2 increase of DiscoDivas over the conventional PRS fine-tuned in a matched
sample when tested in admixed individuals. The x-axis shows the simulated number of causal SNPs.
The horizontal bar shows the mean relative R^2 increase and the color of the horizontal bar indicates the
p-value of the paired t-test of DiscoDivas PRS R^2 and conventional PRS R^2, with cyan being p-
value<0.0005, dark blue being p-value<0.05 and grey being p-value>0.05. In panels a, b, and c, the
causal SNP effect sizes are constant across different populations. The annotation texts on the top of
each panel shows the sample size of discovery GWAS of different populations and the distribution of
causal SNP effect sizes.

245
Although the comparison between DiscoDivas and the conventional method of fine-
tuning PRS with matched ancestry sample in a single test iteration usually showed
no statistical significance due to the small numeric differences, the paired t-test of
DiscoDivas R^2 and the conventional PRS R^2 over the 20 iterations better clarified
significant differences. When effect sizes of causal SNPs were held constant across
different ancestries (Figure 2 panel a, b, and c), the PRS generated by DiscoDivas
had comparable accuracy with the PRS fine-tuned using matched data. We noticed
that when the sample size of non-European discovery GWAS dropped and the
dataset was relatively more Eurocentric, the advantage of DiscoDivas became less
statistically significant. In Figure 2 panel d, we compared DiscoDivas and the
conventional PRS method of fine-tuning the PRS with matched ancestry in the
scenario where causal SNPs were shared across all populations, but the effect sizes
varied linearly in the PCA space. The advantage of DiscoDivas over conventional
PRS method was more obvious in this scenario than when the effect sizes were
constant across populations (Figure 2 panel a and d), presumably because
personalized PRS combination with DiscoDivas better captured the changing effect
sizes for the admixed testing sample. In all the scenarios tested, the advantage of
DiscoDivas was least statistically significant when the number of causal SNPs was
10,000 but still significant when the number of causal SNPs was 1,000. Notably, the
accuracy of both DiscoDivas and the conventional PRS method was the lowest when
the number of causal SNPs was 10,000 (Supplementary Figure 1), indicating that the
difference of the two PRS methods became less obvious when the input data
became increasingly underpowered.
269
When predicting the individuals that are usually classified as single ancestries, i.e.
AFR, EAS, EUR, and SAS, DiscoDivas showed no statistically significant difference
or a slight advantage over the conventional PRS method (Supplementary Figure 2).
When predicting AMR individuals, we used admixed fine-tuning data (OTH) to fine-
tune the conventional PRS due to the small sample size of the AMR dataset. The
PRS performance when testing in the AMR dataset was similar as in admixed data
but the statistical significance was weaker, potentially due to the small sample size

and the high heterogeneity of the AMR dataset. In general, DisocDivas showed its
clearest advantage over the conventional method of fine-tuning PRS with matched
PRS when the testing data and the fine-tuning data for the conventional method were
of different ancestries.
281
282

Biobank data results

284 We downloaded publicly available summary statistical data of body-mass index (BMI),
285 high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL),
286 total cholesterol (TC), triglycerides (TG), systolic blood pressure (SBP), diastolic
287 blood pressure (DBP), coronary artery disease (CAD), and diabetes mellitus (DM2)
288 and adjusted the SNP effect size using LDpred2 as described previously[5].
289
For the quantitative traits, we used the fine-tuning samples of AFR, EAS, EUR, SAS,
and admixed (OTH) ancestry to fine-tune the model. The remaining UKBB samples
were used as the testing data. The results for empiric quantitative trait data were
highly aligned with the simulation results (Figure 4): DiscoDivas showed a robust
advantage over the conventional PRS method of fine-tuning PRS with matched or
similar ancestry samples when compared across the 7 traits in the admixed testing
dataset. When predicting AFR, EAS, EUR, and SAS, DiscoDivas and the
conventional PRS method had similar performance. The results of both methods in
AMR testing dataset had large deviations due to the small sample size and greater
genetic heterogeneity of the AMR data.
300
301

302
303 **Figure 3 Relative R^2 increase of DiscoDivas over the conventional PRS fine-tuned in a matched**
304 **sample.** The x-axis shows the population in which the PRS was tested. We used OTH as the fine-tuning

For the binary traits coronary artery disease (CAD) and type 2 diabetes (DM2)
(Figure 4), we used the AFR, EAS, EUR, SAS, AMR, and OTH (i.e., unclassified)
samples from AoU as the fine-tuning data and tested in AFR, EAS, EUR, SAS, and
OTH individuals in UKBB and AFR, EAS, EUR, SAS, and AMR individuals in MGBB.
The DiscoDivas PRS were based on the PRS fine-tuned in AFR, EAS, EUR, and
SAS and used the default assumption that the PRS fine-tuned from all the samples
were of similar quality even though the sample sizes of both discovery GWAS and
the fine-tuning samples were not balanced across different ancestries. AMR in UKBB
was excluded because of the small sample size (N=669).
318
The PRS fine-tuned in different single samples and the DiscoDivas PRS had similar
performances. It also appeared that some of the fine-tuning sample could be
underpowered: generally, we expect the PRS fine-tuned in the matched sample to
perform the best in the testing samples, but PRS fine-tuned in larger fine-tuning data
performed better than PRS fine-tuned in smaller fine-tuning data in general. For
example, the PRS fine-tuned in EAS AoU data performed worse than other PRS in
both MGBB and UKBB EAS data and had low accuracy in other testing data as well;
the CAD PRS fine-tuned in EUR performed better than all the other PRS in all the
testing data and the effective sample size of EUR CAD fine-tuning data was much
larger than all the other fine-tuning data.
329
330

332
333 **Figure 4 PRS performance for coronary artery disease (CAD) and type 2 diabetes (DM2) tested in**
334 **UKBB and MGBB.** The plot shows OR per SD with the error bar showing 95% CI. The sub-panels show
335 that population of the testing sample and the different colors show the method for generating the PRS,
336 either fine-tuning in a single sample or combining the PRS using DiscoDivas.

Discussion

We propose a new method, DiscoDivas, to interpolate the PRS for diverse, especially
admixed, ancestries with a generalized framework that does not requiring binning
into discrete ancestries. Our results shows that the accuracy of DiscoDivas was
comparable to or greater than the conventional method, i.e. fine-tuning using the
matched population sample when available. In addition, when generating PRS for a
wide range of ancestries, DiscoDivas did not require shifting from several sets of
PRS weights fine-tuned in discrete samples while remaining matched with the
ancestry information. Our method provides a new solution to generate PRS for
underrepresented, generally admixed, populations and as well as generate a
harmonized PRS model across different ancestries.
349
The performance of our method depends on the quality of both the discovery GWAS
data and the fine-tuning data. As shown in the simulation test, discovery GWAS
datasets that represent diverse ancestries with sufficient sample size will increase
the accuracy of interpolated PRS generated by DiscoDivas. On the contrary,
Eurocentric and underpowered discovery GWAS datasets would limit the advantage
of DiscoDivas over the conventional PRS method. This might partly explain the
limited advantage of DiscoDivas when predicting binary traits: the discovery GWAS
datasets were highly Eurocentric and the GWAS, especially the non-European

cohorts, could be more underpowered than quantitative trait GWAS. Furthermore, the
PRS fine-tuned in fine-tuning datasets of insufficient sample size will be overfitted
and cannot be used to fairly evaluate the performance of either the conventional PRS
method or DiscoDivas. We aimed to address this issue by only using traits that 1)
had effective sample sizes larger than 200 in all the fine-tuning samples, and 2) had
high-quality phenotyping data in both the fine-tuning datasets and the testing
datasets, However, Asian populations were largely under-represented in the current
public biobanks: the effective sample size of many binary traits in EAS or SAS can be
as small as <200 even in AoU, the most diverse and large-scale largely publicly-
available biobank we had access to. This limited our choice for binary traits to only
CAD and DM2. One additional limitation of our method is that DisoDivas does not
consider the local ancestry information, which improve PRS predictions in various
research[24,29,30], especially PRS prediction of newly admixed populations[31].
371
Our research underscores the notion that non-European populations, both admixed
and singe-ancestry populations, remain largely under-represented in the existing
genetic data. Furthermore, some potential extensions of our method will not become
possible until we collect more diverse and larger datasets. First, our method has not
been designed nor tested for extrapolating data, e.g. generating PRS for continental
African samples based on African American, European, and Asian samples. Even
though it is mathematically plausible to alter our method to extrapolate the PRS, we
lack data such as continental African samples to test the method. Secondly, we
currently only consider the assumption that the most informative genome-wide PRS
weight shifts linearly in the PCA space. Although more complicated PRS interpolation,
e.g. interpolation guided by local ancestry information [24,29,30], pathway-specific[32,33]
and annotation-guided[34] PRS weights and polynomial interpolation[35,36], can possibly
further improve the PRS accuracy, training such complicated models would require
collecting much larger and more diverse datasets than the existing data. Finally,
additional biological insights could be revealed by interpolating PRS if genetic data of
all the involved diverse ancestries are of sufficient power. In this case, the differences
between interpolated PRS and the PRS trained using the matched ancestry would
indicate the population- or sample- specific factors absent in the interpolation model,
e.g. population-specific genetic variance[37], complicated population stratification
involving cofounding factors[38,39], sample/ancestry-specific modifiers like local
adaptation[38], gene x environment interactions[40] or other factors that contribute to the
genetic variant frequency or effect size in these samples/ ancestries.
394
In conclusion, our method provides a new option to treat the ancestry information as
a continuous variable and interpolate a harmonized PRS for diverse ancestries.
Notably, although our method was developed primarily to calculate PRS when the
matched fine-tuning datasets were unavailable, our research showed that
successfully interpolating PRS required sufficient input data and highlighted the need
to collect genetic data for underrepresented populations. We believe that more
diverse and larger data collected in the coming future will enable the development of
new methods of interpolating PRS and the elucidation of the genetic basis of
complex traits.
404

Methods

Calculation of 1000 Genomes-based PCA and Euclidean distance

We use 1000 Genomes as the reference panel for PCA calculation. The PCA should be based on SNPs that are constantly included in as many samples as possible to enable the use of wide-ranging discovery GWAS and fine-tuning datasets. We started with the Hapmap3 SNPs for this set of SNPs, which has been widely used as a subset of SNPs that approximates the feature of genome-wide common SNPs in many recent studies that involve multi-ancestry prediction [6,25,26,41]. We further filtered for the SNPs likely to be frequently genotyped or imputed with relatively high quality by most samples based on the 1000 Genome data: Hapmap3 SNPs were first extracted from the five super-populations, Africans (AFR), Admixed Americans (AMR), East Asians (EAS), Europeans (EUR) and South Asians (SAS) of the 1000 Genomes. Secondly, SNPs described as the following were excluded: 1) of minor allele frequency lower than 1% in any of the super-population, 2) of minor allele frequency lower than 5% in the combined 1000 Genomes data, and 3) in the long-range LD region (25Mb – 35Mb by hg19 assembly on chromosome 6 and 7Mb – 13Mb on chromosome 8). To calculating the PCA loading, the QC'ed SNPs of the five super-populations were merged then pruned using the PLINK2 function "indep-pairwise" with the parameter "200 100 0.1" - namely the pruning was performed using window size = 200kb, step size = 100, and phased-hardcall-r^2= 0.1. The principal components and the SNP loadings are calculated using PLINK2 function "pca" with the parameter "allele-wts" based on the pruned SNPs.

Based on the protocol suggested on the PLINK2 website (https://www.cog-genomics.org/plink/2.0/score#pca_project), we projected samples for fine-tuning and PRS testing into the PCA space as describe above by calculation the linear score, i.e. the sum of alternative alleles weighted by the SNP effect size, using the PLINK2 function "score" with the SNP loadings as effect size. The original online protocol suggested linear score should be first scaled to standard variation and then rescaled by multiplying the square root of eigenvalue. However, the actual standard deviation of a sample in the same PCA space varies with the homogeneity and the ancestry of the sample. Forcing the PCA of all the samples to have the same standard deviation will cause inconsistent scaling when the samples can be of different ancestries. Therefore, we directly calculated the PCA from sum basic linear score based on the SNP loadings as generated above without any further scaling. The PCA in this study was the sum basic linear score calculated using the PLINK2 function "score" with the parameter "cols=+scoresums'". For large samples whose genotype data were divided into per-chromosome files, the same commands were used to calculate per-chromosome score and the genome-wide score was the sum of the score of all the autosomes.

In DiscoDivas' default setting, the genetic distance between two individuals is defined as the Euclidian distance between the PCA of the two individuals. When the genetic distance calculation involves a sample, we use the median point to present the whole sample.

We also explored the relationship between number of PCs included in the calculation

453 and the Euclidean distance calculated (Supplementary Figure 9) and the distance
454 calculated converged when the number of PCs was larger than 6 in our tests. In our
455 analysis we use the top 10 PCs to calculate the PCs.
456

Genetic ancestry reference

We noticed that the protocol of generating top PCs for ancestry references varied in
previous publications. In our pilot test (see supplementary resuts section entitled
'Pilot test of generating PCA based on less QC'ed SNPs'), we compared the ancestry
reference based on Hapmap3 SNP without any QC and found the result to be highly
correlated. We used the same set of PCs based on QC'ed SNP as described in
section 'Calculation of 1000 Genomes-based PCA and Euclidean distance' for both
genetic ancestry reference and Euclidean distance calculation for data consistency.
465

Random forest model of 100 trees was trained based on the 1000 Genome data. The
out-of-bag estimate of error rate stabilize at the level of 0.28% after the number of
PCs passed 5. We used the model using the top 6 PCs to infer the genetic ancestry
of UK Biobank individuals and the Mass General Brigham Biobank individuals. The
genetic ancestry of an individual was assigned to any of the five ancestries
represented in the 1000 Genomes reference data, i.e. AFR, AMR, EAS, EUR and
SAS, if the highest probability of an individual belonging to that ancestry passed a
threshold. If none of the ancestries had a probability above the threshold, the
individuals were assigned as other (OTH), which indicated that the individual was of
admixed ancestries. With the consideration of the sample size and confirmed by
visual inspection, the threshold of probability for UK Biobank and the Mass General
Brigham Biobank was 0.9 and 0.8 respectively.
478

Data

UK Biobank
The UK Biobank (UKBB) is a volunteer sample of approximately 500,000 adults aged
40-69 upon enrollment living in the United Kingdom recruited since 2006[42]. UKBB
data used in this research were first QC'ed with the following process: Remove the
individuals meeting the criteria that indicate low genotype quality or contamination: 1)
have missing genotype rate larger than 0.02; 2) have genotype-phenotype sex
discordance; 3) are identified as having excess heterozygosity and missing rates; 4)
are identified as putatively carrying sex chromosome configurations that are not
either XX or XY; 5) appeared to have unreasonably large numbers of relatives. From
the remaining samples, individuals from a group of multiple individuals that are closer
than 3rd-degree relatives were retained. 415,402 individuals were left after the QC.
390,037 were self-identified as EUR, 7,039 AFR, 8,652 non-Chinese Asian (ASN),
1430 Chinese (CHN) and 6572 unknown or not answered, and 1672 as admixed
(MIX). The genetic ancestry referred from PC was largely correlated with the self-
reported race, with 385,038 EUR, 7,450 AFR, 8,298 SAS, 2,163 EAS, 669 AMR and
11,784 other (OTH) or admixed.
496

In the PRS test, UKBB samples were grouped by their genetic ancestry (see section
'Genetic ancestry reference'). The fine-tuning datasets for the single-ancestry
populations (AFR, EAS, EUR and SAS) were based on 1.3k randomly selected
samples whose self-report ancestry matched with their genetic ancestry and the

probability of random forest = 1. The fine-tuning dataset for admixed ancestry (OTH)
is 1.3k randomly selected samples of individuals of OTH genetic ancestry (see
Supplementary Figure 3). AMR didn't have its corresponding fine-tuning dataset due
to its small sample size and we used OTH fine-tuning datasets as a proxy since the
two genetic ancestries had similar PCA. The remaining individuals of UKBB were
used as testing data.
507
The quantitative trait of the UKBB samples was the measurement collected after the
participants enrolled. The lipid trait measurement was adjusted for cholesterol-
lowering medication by dividing TC by 0.8 and LDL by 0.7 as before[43]. Cases of
coronary artery diseases (CAD) are defined using the definition described
previously[24]; Cases of diabetes are defined as ever report the following code: E10X,
E11X, E12X, E13X, and E14X where X can be any integer between 0 to 9 in the
ICD10 diagnosis code.
515
516 UKBB participants provided consent in accordance with the primary IRB protocol,
517 and the Massachusetts General Hospital IRB approved the present secondary data
518 analysis of the UKBB data under UKBB application 7089.
519

Mass General Brigham Biobank
The Mass General Brigham Biobank (MGBB) is a volunteer sample of approximately
142,000 participants receiving medical care in the Mass General Brigham health care
system recruited starting 2010. 53,306 MGBB participants underwent genotyping via
Illumina Global Screening Array (Illumina, CA). MGBB genotype data was quality
controlled, imputed and assigned one of the populations AFR, AMR, EAS, EUR, SAS
using K-nearest neighbor model as described previously[44]. The phenotype data of
CAD and diabetes are drawn from PheCodes based on International Classification of
Diseases codes, Nineth (ICD9)110 and Tenth (ICD10) revisions, from the EHR as
described previously[32]. MGBB participants provided consent in accordance with the
primary IRB protocol, and the Massachusetts General Hospital IRB approved the
present secondary data analysis.
532

All of Us Research Program
The *All of Us* (AoU) Research Program is a volunteer sample of more than one
million United States residents recruited starting 2016. AoU aims to engage
communities previously underrepresented in biomedical research in the United
States and beyond[45]. In the present analysis, genetic data from the v7 245,394
participants who were genotyped using short read whole genome sequencing
(srWGS) data. Hapmap3 SNPs were extracted for the callset with the threshold of
(AF) > 1% or population-specific allele count (AC) > 100. Related individuals were
pruned according to the information provided by AoU. Due to the inclusive data
collection, we didn't excluded individuals whose self-report gender were different with
their assigned sex at birth and used the combination of self-report gender and
assigned sex as one of the covariates. The predicted ancestry information was
provided by AoU[46]. The phenotypes were defined as described in previous research
by Buu *et al*[47].
547

Simulated data
The simulated GWAS summary statistics were based on simulated genotype data
based on 1000 Genomes reference[6]. Only Hapmap3 SNPs were included in the
simulation. Causal SNPs were randomly selected from the Hapmap3 SNPs and
simulated per allele effect size following normal distribution. The ladder of causal

SNP number was 100, 1000, 3000, 10000 and the heritability in each of the
population was 0.6. The causal SNP effect size was simulated as either constant
across populations or varying linearly in the PCA space.
The phenotype is the sum of genetic burden and non-genetic factor:

$$phenotype_i = \sum \beta_j x_{j,i} + E_i$$

557 where the $phenotype_i$ and E_i were the phenotype and non-genetic factor of individual
558 i; β_j was the effect size of causal SNP j, and $x_{j,i}$ was the number of risk alleles of
559 individual i in SNP j.
560
We used the PLINK2[28] to calculate the genetic burden based on the simulated causal
SNPs and effect size and used R to simulate the non-genetic factors, scale the
genetic burden and non-genetic factor, and generate a phenotype of heritability set to
be 0.6. We used up to 100k individuals per population to generate the summary
statistical GWAS as the discovery data for the PRS test. The rest simulated data
were left out for the fine-tuning and testing datasets. The summary statistics GWAS
were generated based on the simulated genotype data and phenotype data using the
'--glm' function of PLINK2.
569
In addition to the completely simulated data, we generated more realistic fine-tuning
and testing datasets of a wider ancestry range by using the QC'ed genotype data
from UKBB described in the section 'Biobank data.' We simulated the genetic burden,
non-genetic factor, and phenotype based on the real-life UKBB genotype data with
the same pipeline and parameters. A more detailed description of simulating the data
were given in section 'Generating data for simulation analysis' in the supplementary
text.
577

Acknowledgement

579 We thank the participants and staff of the UK Biobank (application 7089), Mass
580 General Brigham Biobank, and *All of Us* Research Program. We thank Ying Wang,
581 Paul O'Reilly, Raymond Walters for helpful discussion and advice.
582

Contributions

Y.R. and P.N. designed the project; Y.R. developed the statistical methods and
programmed the code for DiscoDivas. A.P curated the summary statistical GWAS.
R.B, S.K, L.H, B.T, and W.H participated in application for the access to the Biobank
data and the data curation. Y.R and R.B performed the data analysis. R.B, B.T, H.Z,
and N.C contributed to the method development. Y.R. and P.N wrote the manuscript.
A.P. and N.C. provided critical revision for the manuscript. All the authors reviewed
and approved the final version of the manuscript.
591

Data Availability

The access to biobank data (UK Biobank, Mass General Brigham Biobank, and All of

US Research Program) were gained upon application. The simulated genotype data
based on 1000 Genomes were downloaded from
https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/COXHAP
;The resource of summary statistics GWAS data used to generate PRS were given in
the supplementary file. The 1000 Genome raw reference genotype data were
downloaded from https://cncr.nl/research/magma/.
600

Code Availability

602 The scripts of running DiscoDivas and other supporting files can be found at
603 https://github.com/YunfengRuan/DiscoDivas; PRS-CS:
604 https://github.com/getian107/PRScs; LDpred2:
605 https://privefl.github.io/bigsnpr/articles/LDpred2; PLINK2: https://www.cog-
606 genomics.org/plink/2.0/.
607

Reference

1. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may
exacerbate health disparities. *Nat Genet* **51**, 584–591 (2019).
2. Miao, J. *et al.* Quantifying portable genetic effects and improving cross-
ancestry genetic prediction with GWAS summary statistics. *Nat Commun* **14**,
832 (2023).
3. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse
populations. *Nat Genet* **54**, 573–580 (2022).
4. Jin, J. *et al.* MUSSEL: Enhanced Bayesian Polygenic Risk Prediction
Leveraging Information across Multiple Ancestry Groups. *bioRxiv*
2023.04.12.536510 (2023) doi:10.1101/2023.04.12.536510.
5. Patel, A. P. *et al.* A multi-ancestry polygenic risk score improves risk prediction
for coronary artery disease. *Nat Med* **29**, 1793–1803 (2023).
6. Zhang, H. *et al.* A new method for multiancestry polygenic prediction improves
performance across diverse populations. *Nat Genet* **55**, 1757–1768 (2023).
7. Ding, Y. *et al.* Polygenic scoring accuracy varies across the genetic ancestry
continuum. *Nature* **618**, 774–781 (2023).
8. Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L. & Bonham, V. L. Lack Of
Diversity In Genomic Databases Is A Barrier To Translating Precision
Medicine Research Into Practice. *Health Aff* **37**, 780–785 (2018).
9. The All of Us Research Program Genomics Investigators. Genomic data in the
All of Us Research Program. *Nature* **627**, 340–346 (2024).
10. Fatumo, S. *et al.* Polygenic risk scores for disease risk prediction in Africa:
current challenges and future directions. *Genome Medicine* vol. 15 Preprint at
https://doi.org/10.1186/s13073-023-01245-9 (2023).
11. Dokuru, D. R., Horwitz, T. B., Freis, S. M., Stallings, M. C. & Ehringer, M. A.
South Asia: The Missing Diverse in Diversity. *Behav Genet* **54**, 51–62 (2024).
12. Stefflova, K. *et al.* Dissecting the Within-Africa ancestry of populations of
African descent in the Americas. *PLoS One* **6**, (2011).
13. Harlemon, M. *et al.* A custom genotyping array reveals population-level
heterogeneity for the genetic risks of prostate cancer and other cancers in
Africa. *Cancer Res* **80**, 2956–2966 (2020).

14. Anagnostou, P. *et al.* Inter-individual genomic heterogeneity within European
population isolates. *PLoS One* **14**, (2019).

15. Pan, Z. & Xu, S. Population genomics of East Asian ethnic groups. *Hereditas*
vol. 157 Preprint at https://doi.org/10.1186/s41065-020-00162-w (2020).

16. Khera, A. V *et al.* Whole-Genome Sequencing to Characterize Monogenic and
Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial
Infarction. *Circulation* **139**, 1593–1602 (2019).

17. Duncan, L. *et al.* Analysis of polygenic risk score usage and performance in
diverse human populations. *Nat Commun* **10**, 3328 (2019).

18. Wang, M. *et al.* Validation of a Genome-Wide Polygenic Score for Coronary
Artery Disease in South Asians. *J Am Coll Cardiol* **76**, 703–714 (2020).

19. Ge, T. *et al.* Development and validation of a trans-ancestry polygenic risk
score for type 2 diabetes in diverse populations. *Genome Med* **14**, 70 (2022).

20. O'Sullivan, J. W. *et al.* Polygenic Risk Scores for Cardiovascular Disease: A
Scientific Statement From the American Heart Association. *Circulation* vol. 146
E93–E118 Preprint at https://doi.org/10.1161/CIR.0000000000001077 (2022).

21. Lewis, C. M. & Vassos, E. Polygenic risk scores: From research tools to
clinical instruments. *Genome Medicine* vol. 12 Preprint at
https://doi.org/10.1186/s13073-020-00742-5 (2020).

22. Xiang, R. *et al.* Recent advances in polygenic scores: translation, equitability,
methods and FAIR tools. *Genome Medicine* vol. 16 Preprint at
https://doi.org/10.1186/s13073-024-01304-9 (2024).

23. Truong, B. *et al.* Integrative polygenic risk score improves the prediction
accuracy of complex traits and diseases. *Cell Genomics* **4**, (2024).

24. Wang, Y. *et al.* Polygenic prediction across populations is influenced by
ancestry, genetic architecture, and methodology. *Cell Genomics* **3**, (2023).

25. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic
prediction via Bayesian regression and continuous shrinkage priors. *Nat
Commun* **10**, 1776 (2019).

26. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger.
Bioinformatics **36**, 5424–5431 (2021).

27. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**,
68–74 (2015).

28. Chang, C. C. *et al.* Second-generation PLINK: Rising to the challenge of larger
and richer datasets. *Gigascience* **4**, (2015).

29. Atkinson, E. G. *et al.* Tractor uses local ancestry to enable the inclusion of
admixed individuals in GWAS and to boost power. *Nat Genet* **53**, 195–204
(2021).

30. Sun, Q. *et al.* Improving polygenic risk prediction in admixed populations by
explicitly modeling ancestral-differential effects via GAUDI. *Nat Commun* **15**,
(2024).

31. Marnetto, D. *et al.* Ancestry deconvolution and partial polygenic score can
improve susceptibility predictions in recently admixed individuals. *Nat
Commun* **11**, (2020).

32. Xu, Y. *et al.* Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's
Disease (AD) on Rate of Change in Cognitive Function and AD-Related
Biomarkers Among Asymptomatic Individuals. *Journal of Alzheimer's Disease*
94, 1587–1605 (2023).

33. Tubbs, J. D. *et al.* Pathway-Specific Polygenic Scores Improve Cross-Ancestry
Prediction of Psychosis and Clinical Outcomes. Preprint at
https://doi.org/10.1101/2023.09.01.23294957 (2023).

34. Miao, J. *et al.* Quantifying portable genetic effects and improving cross-
ancestry genetic prediction with GWAS summary statistics. *Nat Commun* **14**,

693 (2023).

35. Kumar, R., Bhattacharya, S. & Murmu, G. Exploring Optimality of Piecewise Polynomial Interpolation Functions for Lung Field Modeling in 2D Chest X-Ray Images. *Front Phys* **9**, (2021).

36. Womersley, R. S. & Sloan, I. H. *How Good Can Polynomial Interpolation on the Sphere Be? Advances in Computational Mathematics* vol. 14 (2001).

37. Choudhury, A. *et al.* Population-specific common SNPs reflect demographic histories and highlight regions of genomic plasticity with functional relevance. *BMC Genomics* **15**, (2014).

38. Rees, J. S., Castellano, S. & Andrés, A. M. The Genomics of Human Local Adaptation. *Trends in Genetics* vol. 36 415–428 Preprint at https://doi.org/10.1016/j.tig.2020.03.006 (2020).

39. Mas-Sandoval, A., Mathieson, S. & Fumagalli, M. The genomic footprint of social stratification in admixing American populations. **12**, 84429 (2023).

40. Patel, R. A. *et al.* Genetic interactions drive heterogeneity in causal variant effect sizes for gene expression and complex traits. *Am J Hum Genet* **109**, 1286–1297 (2022).

41. Yengo, L. *et al.* A saturated map of common genetic variants associated with human height. *Nature* **610**, 704–712 (2022).

42. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).

43. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of lipids. *Nature* **600**, 675–679 (2021).

44. Koyama, S. *et al.* Decoding Genetics, Ancestry, and Geospatial Context for Precision Health. *medRxiv* (2023) doi:10.1101/2023.10.24.23297096.

45. Kathiresan, N. *et al.* Representation of Race and Ethnicity in the Contemporary US Health Cohort All of Us Research Program. *JAMA Cardiol* **8**, 859–864 (2023).

46. Bick, A. G. *et al.* Inherited causes of clonal haematopoiesis in 97,691 whole genomes. *Nature* **586**, 763–768 (2020).

47. Truong, B. *et al.* Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases. *medRxiv* (2023) doi:10.1101/2023.02.21.23286110.